Atlas Trials

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Clinical trial NCT00997334 · COMPLETED

Trial details

NCT number
NCT00997334
Sponsor
David M. Jackman, MD
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2010-02-01
Primary completion
2015-05-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.